Payment overview · 2025
General Payments
$1,000.65
54 reported records · 14 companies
Healthcare provider profile · identity verified
Damon J Thomas, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CRANE, MO · NPI 1023100773
Verified facts
What the public records show
CMS Open Payments records show Damon J Thomas, M.D. received $1,000.65 in general payments during 2025 across 54 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $203.69 | 20.4% | 12 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $111.38 | 11.1% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $106.41 | 10.6% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $92.03 | 9.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $83.21 | 8.3% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $70.43 | 7.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.98 | 7.0% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $54.43 | 5.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.59 | 5.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.70 | 4.8% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $41.54 | 4.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.09 | 3.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.94 | 1.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.23 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,000.65 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $156.97 | 9 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $111.38 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $106.41 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $103.52 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $92.03 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $83.22 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.21 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $69.98 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.00 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $54.43 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $41.54 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.93 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.07 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.05 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 71 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
76 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 589 | 120 |
| Atorvastatin Calcium | Atorvastatin Calcium | 488 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 470 | 85 |
| Omeprazole | Omeprazole | 461 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 448 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 377 | 78 |
| Gabapentin | Gabapentin | 367 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 347 | 71 |
| Alprazolam | Alprazolam | 284 | 34 |
| Metformin Hcl Er | Metformin Hcl | 262 | 57 |
| Losartan Potassium | Losartan Potassium | 255 | 63 |
| Meloxicam | Meloxicam | 252 | 63 |
| Montelukast Sodium | Montelukast Sodium | 250 | 44 |
| Trazodone Hcl | Trazodone Hcl | 238 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 235 | 33 |
| Pregabalin | Pregabalin | 211 | 29 |
| Famotidine | Famotidine | 209 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 208 | 44 |
| Sertraline Hcl | Sertraline Hcl | 193 | 29 |
| Tramadol Hcl | Tramadol Hcl | 178 | 36 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 177 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 173 | 43 |
| Simvastatin | Simvastatin | 167 | 35 |
| Furosemide | Furosemide | 164 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 144 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 32 |
| Atenolol | Atenolol | 137 | 24 |
| Buspirone Hcl | Buspirone Hcl | 133 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 129 | 23 |
| Potassium Chloride | Potassium Chloride | 128 | 27 |
| Lorazepam | Lorazepam | 127 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 127 | 23 |
| Alendronate Sodium | Alendronate Sodium | 125 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 115 | 13 |
| Metformin Hcl | Metformin Hcl | 113 | 19 |
| Carvedilol | Carvedilol | 101 | 23 |
| Finasteride | Finasteride | 99 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 19 |
| Clonazepam | Clonazepam | 93 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 91 | suppressed |
| Prednisone | Prednisone | 89 | 54 |
| Januvia | Sitagliptin Phosphate | 88 | 13 |
| Allopurinol | Allopurinol | 86 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 85 | 20 |
| Spironolactone | Spironolactone | 85 | 16 |
| Baclofen | Baclofen | 82 | 15 |
| Carisoprodol | Carisoprodol | 82 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 82 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 17 |
| Ozempic | Semaglutide | 76 | 16 |
| Trulicity | Dulaglutide | 76 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 13 |
| Lovastatin | Lovastatin | 72 | 15 |
| Eliquis | Apixaban | 71 | 12 |
| Mounjaro | Tirzepatide | 68 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 21 |
| Morphine Sulfate Er | Morphine Sulfate | 58 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 56 | 13 |
| Diazepam | Diazepam | 56 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 53 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 51 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 51 | suppressed |
| Risperidone | Risperidone | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 49 | 13 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | 11 |
| Olanzapine | Olanzapine | 43 | suppressed |
| Chlorthalidone | Chlorthalidone | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 40 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 39 | suppressed |
| Celecoxib | Celecoxib | 39 | suppressed |
| Jardiance | Empagliflozin | 39 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | suppressed |
| Dutasteride | Dutasteride | 38 | suppressed |
| Nystatin | Nystatin | 37 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 11 |
| Cephalexin | Cephalexin | 35 | 30 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 29 |
| Naproxen | Naproxen | 34 | suppressed |
| Zafirlukast | Zafirlukast | 34 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 33 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 32 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Telmisartan | Telmisartan | 31 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Nystop | Nystatin | 29 | 12 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 20 |
| Azithromycin | Azithromycin | 19 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 18 | suppressed |
| Nabumetone | Nabumetone | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Linzess | Linaclotide | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Clobazam | Clobazam | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Soma | Carisoprodol | 12 | suppressed |
| Tegretol | Carbamazepine | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,000.65 · 54 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, REPATHA, REXULTI, Rybelsus, SKYCLARYS, Veozah, YUPELRI, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error